Quanterix Corporation - QTRX STOCK NEWS

Quanterix Corporation (NASDAQ: QTRX) announced that Eli Lilly presented new data from the Phase 2 TRAILBLAZER-ALZ study at AAIC 2021, utilizing Quanterix’ Simoa® technology. The data indicate a significant reduction in blood levels of phosphorylated Tau protein after treatment with donanemab, highlighting Simoa’s role in Alzheimer’s research. More than 80 abstracts based on Simoa technology were presented at the event. Quanterix continues to focus on advancing therapies for neurodegenerative diseases, aiming for earlier detection and improved patient outcomes.

Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q2 2021, achieving a GAAP total revenue of $25.4M, up 93% from $13.1M in Q2 2020. Non-GAAP total revenue increased 86% to $24.4M. Product revenue soared by 175% to $18.7M. Gross margins improved, with Q2 GAAP gross margin at 54.7%, up from 39.7% in 2020. The company also made strides in diagnostics for neurodegenerative diseases, enhancing methodologies for disease progression monitoring. Leadership changes included the appointment of Masoud Toloue as President and Michael Doyle as CFO.

Quanterix Corporation (NASDAQ: QTRX) will release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call is scheduled for 4:30 PM ET, hosted by CEO Kevin Hrusovsky, to discuss the results and provide a business update. Investors can join by calling 833-686-9351 (domestic) or 612-979-9890 (international) and using conference ID 2299526. A live webcast of the call will be available at this link.

Quanterix Corporation (NASDAQ: QTRX) announced the appointment of Michael Doyle as the new Chief Financial Officer (CFO) and Treasurer, effective July 12, 2021. Doyle replaces Shawn Stetson, who served in an interim capacity. Doyle brings significant experience as a public company CFO, having previously worked at Forrester Research, where he oversaw a team of 85 and managed multiple acquisitions while growing revenue from $200M to $500M. His appointment is seen as a strategic move to enhance the company’s prospects in advancing precision health through its digital biomarker analysis technology.

Quanterix Corporation (NASDAQ: QTRX) announced significant research utilizing its Simoa® technology to assess the plasma neurofilament light (NfL) biomarker for neurological disorders. Published in Nature Communications, this study involved 2,269 individuals and aims to enhance non-invasive diagnostics in neurodegenerative conditions. Findings confirm plasma NfL's potential in differentiating disorders and establishing age-related cutoffs vital for clinical applications. The research underscores NfL's role in precision health, bolstering Quanterix’s position as a leader in biomarker analysis.

Quanterix Corporation (NASDAQ:QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 3:50 PM ET. The public can join the webcast via this link, with replays available for 90 days. Additionally, Hrusovsky will appear on The Bio Report podcast on June 3 at 4:00 PM EDT, accessible on various streaming platforms.

Quanterix Corporation (NASDAQ: QTRX) has appointed Masoud Toloue as President, effective June 9, 2021. Toloue brings extensive experience from PerkinElmer, where he significantly grew their diagnostics sector. The company highlighted advancements in diagnostics, particularly in response to COVID-19 and neurological disorders such as Multiple Sclerosis and Alzheimer’s. Toloue's expertise is expected to drive growth as he oversees the diagnostics business and corporate development. Quanterix aims to enhance precision health through innovative digital biomarker technology.

Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q1 2021, with total revenue increasing to $27.2M, up from $15.7M in Q1 2020, driven by a 86% rise in product revenues to $18.2M. The company achieved a gross margin of 60.1%, compared to 43.3% the previous year. Notably, Quanterix received Emergency Use Authorization for its Simoa® SARS-CoV-2 N Protein Antigen Test. The firm raised approximately $270M in a follow-on offering, strengthening its financial position. The demand for neurodegenerative disease assays, particularly for Alzheimer’s, remains robust.

Quanterix Corporation (NASDAQ: QTRX) will release its financial results for Q1 2021 on May 5, 2021, after market close. A conference call hosted by CEO Kevin Hrusovsky will take place at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can join by phone or through a live webcast available on Quanterix's website. The company specializes in digitizing biomarker analysis, aiming to enhance precision health through early disease detection and improved treatment methods across various therapeutic areas.